XORTX Therapeutics has completed the acquisition of the Vectus kidney anti-fibrotic asset, including the novel compound VB4-P5, aimed at treating chronic kidney disease (CKD) and kidney fibrosis. This acquisition expands XORTX's pipeline with a pre-IND stage program targeting both rare and common kidney diseases, addressing a significant unmet medical need. The deal was valued at $3 million, paid in shares and warrants, and positions XORTX to develop a potential treatment that could slow or reverse kidney fibrosis, a key factor in CKD progression. The company plans to advance this program alongside its existing clinical-stage kidney and gout therapies.
The global automotive microcontrollers market is projected to grow from USD 15.49 billion in 2025 to USD 34.31 billion by 2035, at a CAGR of 8.28%. Growth is fueled by increasing adoption of advanced driver-assistance systems (ADAS), vehicle electrif...
Sodexo has secured a major global contract to provide catering services across more than 130 Meta sites in over 30 countries. This large-scale partnership includes diverse locations such as headquarters, campuses, data centers, and conference centers...
Solana (SOL) has gained about 30% from its June low, trading around $78 and surpassing its 50-day EMA. The token's upward momentum is supported by increased speculative trading and a new SuperTrend buy signal, the first since October 2025. However, i...
Kenmare Resources reported weaker-than-expected production in the first half of 2026 due to commissioning delays at its Wet Concentrator Plant A, with ilmenite output down 40% year on year in Q2. Despite this, shipments increased by 53% as the compan...
Ramsdens Holdings PLC shares rose 13.6% to 670p following an improved takeover offer from US pawnbroking group FirstCash. FirstCash increased its cash bid to 675p per share from 600p, raising the total offer value to up to £232 million, including div...
